{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:14:35Z","timestamp":1790172875344,"version":"4.1.0"},"reference-count":26,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0499","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:12:39Z","timestamp":1525237959000},"source":"Crossref","is-referenced-by-count":21,"title":["The Treatment of Secondary Hemochromatosis"],"prefix":"10.3238","author":[{"given":"Norbert","family":"Gattermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2009,7,24]]},"reference":[{"key":"10.3238\/arztebl.2009.0499_ref1","doi-asserted-by":"crossref","unstructured":"Buja LM, Roberts WC: Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209\u201321.","DOI":"10.1016\/0002-9343(71)90240-3"},{"key":"10.3238\/arztebl.2009.0499_ref2","unstructured":"Gattermann N, Porter JB, Lopes LF, Seymour J: Consensus statement on iron overload in myelodysplastic syndromes. Hematology\/Oncology Clinics of North America 2005; 19 (Suppl 1): 18\u201325."},{"key":"10.3238\/arztebl.2009.0499_ref3","doi-asserted-by":"crossref","unstructured":"Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS et al.: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319\u201324.","DOI":"10.1056\/NEJM198102053040603"},{"key":"10.3238\/arztebl.2009.0499_ref4","doi-asserted-by":"crossref","unstructured":"Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T et al.: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288\u201399.","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x"},{"key":"10.3238\/arztebl.2009.0499_ref5","doi-asserted-by":"crossref","unstructured":"di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007; 78: 540\u20132.","DOI":"10.1111\/j.1600-0609.2007.00840.x"},{"key":"10.3238\/arztebl.2009.0499_ref6","doi-asserted-by":"crossref","unstructured":"Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594\u2013603.","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"10.3238\/arztebl.2009.0499_ref7","doi-asserted-by":"crossref","unstructured":"Leitch H: Improving clinical outcome in patients wtih myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007; 31 (Suppl 3): 7\u20139.","DOI":"10.1016\/S0145-2126(07)70460-5"},{"key":"10.3238\/arztebl.2009.0499_ref8","doi-asserted-by":"crossref","unstructured":"Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL: Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632\u20139.","DOI":"10.1182\/blood-2002-09-2754"},{"key":"10.3238\/arztebl.2009.0499_ref9","unstructured":"di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D"},{"key":"10.3238\/arztebl.2009.0499_ref10","doi-asserted-by":"crossref","unstructured":": Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008; 93: 1385\u20138.","DOI":"10.3324\/haematol.12759"},{"key":"10.3238\/arztebl.2009.0499_ref11","doi-asserted-by":"crossref","unstructured":"Borgna-Pignatti C, Cohen A: Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130: 86\u20138.","DOI":"10.1016\/S0022-3476(97)70314-7"},{"key":"10.3238\/arztebl.2009.0499_ref12","doi-asserted-by":"crossref","unstructured":"Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G: Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95: 2776\u20139.","DOI":"10.1182\/blood.V95.9.2776.009k26_2776_2779"},{"key":"10.3238\/arztebl.2009.0499_ref13","doi-asserted-by":"crossref","unstructured":"Bousquet J, Navarro M, Robert G, Aye P, Michel FB: Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet 1983; 2: 859\u201360.","DOI":"10.1016\/S0140-6736(83)90785-7"},{"key":"10.3238\/arztebl.2009.0499_ref14","doi-asserted-by":"crossref","unstructured":"Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al.: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567\u201373.","DOI":"10.1056\/NEJM199409013310902"},{"key":"10.3238\/arztebl.2009.0499_ref15","doi-asserted-by":"crossref","unstructured":"Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V et al.: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330.","DOI":"10.1046\/j.1365-2141.2002.03554.x"},{"key":"10.3238\/arztebl.2009.0499_ref16","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516\u201320.","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"10.3238\/arztebl.2009.0499_ref17","doi-asserted-by":"crossref","unstructured":"Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583\u20137.","DOI":"10.1182\/blood-2002-10-3280"},{"key":"10.3238\/arztebl.2009.0499_ref18","doi-asserted-by":"crossref","unstructured":"Pennell DJ: Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738\u201344.","DOI":"10.1182\/blood-2005-07-2948"},{"key":"10.3238\/arztebl.2009.0499_ref19","doi-asserted-by":"crossref","unstructured":"Hoffbrand AV, Cohen A, Hershko O: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17\u201324.","DOI":"10.1182\/blood-2002-06-1867"},{"key":"10.3238\/arztebl.2009.0499_ref20","doi-asserted-by":"crossref","unstructured":"Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A et al.: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876\u201384.","DOI":"10.1161\/CIRCULATIONAHA.106.648790"},{"key":"10.3238\/arztebl.2009.0499_ref21","unstructured":"Gattermann N, Musch A: Deferasirox. Orale Therapie bei transfusionsbedingter Eisen\u00fcberladung. Arzneimitteltherapie 2007; 25: 240\u20137."},{"key":"10.3238\/arztebl.2009.0499_ref22","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Cohen A, Piga A et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2005; 107: 3455\u201362.","DOI":"10.1182\/blood-2005-08-3430"},{"key":"10.3238\/arztebl.2009.0499_ref23","doi-asserted-by":"crossref","unstructured":"Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD et al.: Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 2008; 80: 168\u201376.","DOI":"10.1111\/j.1600-0609.2007.00985.x"},{"key":"10.3238\/arztebl.2009.0499_ref24","doi-asserted-by":"crossref","unstructured":"Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455\u201362.","DOI":"10.1182\/blood-2005-08-3430"},{"key":"10.3238\/arztebl.2009.0499_ref25","doi-asserted-by":"crossref","unstructured":"Nathan DG: Oral iron chelation: new drug, old rules. Blood 2008; 111: 483\u20134.","DOI":"10.1182\/blood-2007-11-123349"},{"key":"10.3238\/arztebl.2009.0499_ref26","doi-asserted-by":"crossref","unstructured":"Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E: Recent developments in iron chelator therapy. Klin P\u00e4diatr 2007; 219: 158\u201365.","DOI":"10.1055\/s-2007-973845"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:39:07Z","timestamp":1638851947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,24]]},"references-count":26,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0499","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,24]]}}}